Ulobetasol lotion - Therapeutics Incorporated

Drug Profile

Ulobetasol lotion - Therapeutics Incorporated

Alternative Names: 000-0551; Halobetasol lotion - Therapeutics Incorporated

Latest Information Update: 13 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Therapeutics Incorporated
  • Class Anti-inflammatories; Antiallergics; Corticosteroids; Small molecules
  • Mechanism of Action Phospholipase A2 inhibitors; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Plaque psoriasis

Most Recent Events

  • 13 Apr 2016 No recent reports on development identified - Phase-III for Plaque psoriasis in USA (Topical)
  • 01 Mar 2014 Therapeutics Incorporated completes a phase III trial in Plaque psoriasis in USA (NCT01882647)
  • 31 Dec 2013 Therapeutics Incorporated completes a phase III trial for Plaque psoriasis in USA (NCT01871402)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top